Formulation Development of Mouth Dissolving Film of Etoricoxib for Pain Management. (26th January 2015)

• Record Type: Journal Article
• Authors: Senthilkumar, K.; Vijaya, C.
• Other Names: Conway Barbara R. Academic Editor.
• Is Part Of: Advances in pharmaceutics. Volume 2015(2015)
• Publication Date: 2015-01-26
• Subjects: Pharmacology -- Periodicals; Drugs -- Dosage forms -- Periodicals; Solid dosage forms; Dosage Forms; Periodicals; 615.19
• DOI: 10.1155/2015/702963
• Languages: English
• ISSNs: 2356-6841

Abstract

Abstract : Etoricoxib is a potent, orally active, and highly selective COX-2 inhibitor that exhibits anti-inflammatory, analgesic, and antipyretic activities. The present research was undertaken to develop mouth dissolving films of etoricoxib to have rapid onset of action. Mouth dissolving film (MDF) is a better alternate to oral disintegrating tablets due to its novelty, ease of use, and the consequent patient compliance. Solubility enhancement and taste masking of etoricoxib were the two challenges solved by formulating drug-inclusion complex with beta-cyclodextrin (BCD). MDF prepared by solvent casting etoricoxib-BCD complex along with HPMC as film forming polymer was found to possess desirable physicomechanical properties. In vitro release of etoricoxib from MDF in simulated salivary fluid and 0.1 N HCl was more than 95% within 2 minutes. Taste masking and in vivo disintegration were in acceptable range as assessed by human volunteers. Etoricoxib MDF was further characterized by differential scanning calorimetry, powder X-ray diffraction, and scanning electron microscopy. The index of analgesia shown by etoricoxib MDF was comparable to that of immediate release tablets (100% activity within 40 minutes) in animal studies. Conclusively, the present study documents the development of a commercially viable formula for an MDF of etoricoxib with rapidity in pain management.